Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK.
Drugs R D. 2011;11(1):13-27. doi: 10.2165/11539760-000000000-00000.
Osteoarthritis (OA), also called degenerative joint disease, is the most frequently occurring chronic musculoskeletal disease, particularly affecting the aging population. The use of viscosupplementation, i.e. intra-articular (IA) hyaluronic acid (HA) drug therapy, to treat OA, is growing worldwide, due to important results obtained from several clinical trials, which reported IA HA-related improvements in functional activity and pain management. This review is an update of the IA use of this compound in the treatment of OA, with clinical evidence from the last few years being discussed and used to delineate new trends for the future.
骨关节炎（OA），也称为退行性关节病，是最常见的慢性肌肉骨骼疾病，尤其影响老年人群。由于几项临床试验取得了重要结果，表明关节内（IA）透明质酸（HA）药物治疗可改善功能活动和疼痛管理，因此，在全球范围内，使用黏弹性补充剂（即 IA 透明质酸[HA]药物治疗）治疗 OA 的情况越来越多。本综述是对该化合物在 OA 治疗中的 IA 使用的更新，讨论了近年来的临床证据，并用于描绘未来的新趋势。
